{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/6311fe9bae5d13001250521f/690d8e88c72b7869e26bdccf?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"What Biotech Investors Look For: The Real Checklist For Funding Your Drug or Device","description":"<p>From pitch decks to de-risking strategies — how to turn promising research into an investible opportunity</p><p><br></p><p>You’ve got strong data and maybe even a breakthrough idea, but can you convince an investor or pharma partner that it’s worth their millions?</p><p><br></p><p>🔍 <strong>What You’ll Learn:</strong></p><p> In this second part of the <em>Drug Discovery Roadmap</em> series, we move from the bench to the boardroom.</p><p> If you’re a STEM researcher or biotech founder wondering what turns great science into an investible opportunity, this episode unpacks it straight from investors, pharma veterans, and researchers who’ve been through the process.</p><p>You’ll learn:</p><p> • How to pitch your science to investors — what to include, what to leave out, and how to get a second meeting.</p><p> • Why a realistic, conservative market size matters more than billion-dollar dreams.</p><p> • The smart ways to <em>de-risk</em> your project — from alternate indications to veterinary and agricultural applications.</p><p><br></p><p>🎯  Play this episode to learn how to make your science fundable and credible in the eyes of those who write the cheques.</p><p><br></p><p>🧠 <strong>About the Guests:</strong></p><p> Recorded live at the 2025 ARCS Drug Discovery Forum, this episode features insights from industry investors and researchers who’ve lived the highs and lows of drug translation:</p><ul><li><strong>Mike Lamprecht</strong>, Investment Manager at Tenmile, on what catches his eye in a biotech pitch (and what sends red flags).</li><li><strong>Dr Wolfgang Jarolimek</strong>, Head of Drug Discovery at Syntara, on why you should never bet everything on one indication.</li><li><strong>Dr Daniel Beard</strong>, Founder and CSO of Shearflow, on how feedback from the Forum reshaped his strategy for stroke therapy.</li><li><strong>Tim Boyle</strong>, CEO of ARCS Australia, on why collaboration and “asking the right questions early” are key to commercial success.</li></ul><p><br></p><p><br></p><p>📌 <strong>Episode Highlights:</strong></p><p> 00:00 Welcome back — what makes a project investible</p><p> 02:00 Tim Boyle on building the bridge between research and industry</p><p> 03:45 The number one startup killer: running out of capital</p><p> 04:00 Mike Lamprecht on how to pitch science to investors</p><p> 06:00 Market size myths — why “$10B market” slides backfire</p><p> 08:00 The antibiotic paradox: when life-saving drugs still fail commercially</p><p> 10:00 Diagnostics, payers, and the hidden gap between science and buyers</p><p> 11:00 Daniel Beard on differentiating his stroke therapy</p><p> 14:00 How to reframe your science for clarity and investor appeal</p><p> 16:00 What clinicians need to see before trials</p><p> 17:00 De-risking your project: alternate indications and sectors</p><p> 19:00 The case for parallel applications — human, veterinary, agriculture</p><p> 20:00 Why every biotech needs backup plans</p><p> 21:00 Closing takeaways: the intersection of science, strategy, and story</p><p><br></p><p>♻️ Share this episode with researchers and biotech scientists and anyone trying to get their science to market. </p>","author_name":"Angelique Greco | Biotech & Health-Tech Expert | STEM Thought Leadership Coach"}